title: [Treatment of osteoarthritis of the knee joint. Efficacy and tolerance to acemetacin slow release in comparison to celecoxib].
abstract: OBJECTIVE
  The aim of this trial was to compare acemetacin (ACE) with celecoxib (CEL) in terms of tolerability and efficacy in the treatment of osteoarthritis of the knee joint.
  
  
  METHODS
  A total of 105 patients (26-64 years old) suffering from primary osteoarthritis (OA) of the knee were enrolled in this international, multicenter, randomized, double blind controlled trial. Fifty three patients were given ACE and 52 CEL. They were treated with either 90 mg bid of slow release ACE or 200 mg bid of CEL for 6 weeks. Additional gastroprotective therapy was not provided. Tolerability was assessed by physical examination, laboratory tests, vital signs and reports of side effects, as well as by patient and physician global assessments. Efficacy parameters comprised pain assessment by visual analogue scale (VAS) and ordinal scale, WOMAC, SF-36 and patient and physician global impressions of efficacy. In addition, acetaminophen consumption was recorded.
  
  
  RESULTS
  In 21 ACE (39.6%) and 19 CEL patients (36.5%), the number of side effects totaled 56 (ACE n=29; CEL n=27) (ns). Mean pain reduction at week 6 was highly significant ( P<0.0001) in both groups and amounted to 38.7 mm (+/-20.3) in the ACE group and to 35.1 mm (+/-18.7) in the CEL group (ns). Very similar results were seen with respect to the other efficacy parameters.
  
  
  CONCLUSIONS
  ACE is not inferior to CEL for the short-term treatment of knee OA in terms of tolerability and efficacy.
authors.affiliation: II. Medizinische Abteilung, NO-Zentrum für Rheumatologie, Humanis-Klinikum Niederösterreich, Landstrasse 18, 2000 Stockerau, Austria. leeb.khstockerau@aon.at
authors.forename: B F
authors.initials: BF
authors.lastname: Leeb
authors.forename: L
authors.initials: L
authors.lastname: Bucsi
authors.forename: B
authors.initials: B
authors.lastname: Keszthelyi
authors.forename: J
authors.initials: J
authors.lastname: Böhmova
authors.forename: M
authors.initials: M
authors.lastname: Valesova
authors.forename: R
authors.initials: R
authors.lastname: Hawel
authors.forename: F
authors.initials: F
authors.lastname: Mayrhofer
authors.forename: F
authors.initials: F
authors.lastname: Singer
authors.forename: F
authors.initials: F
authors.lastname: Aglas
authors.forename: H
authors.initials: H
authors.lastname: Bröll
mesh_terms: D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000068579:Celecoxib; D016001:Confidence Intervals; D003627:Data Interpretation, Statistical; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007213:Indomethacin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D020370:Osteoarthritis, Knee / Q000188:drug therapy*; D010146:Pain / Q000175:diagnosis; D010147:Pain Measurement; D011720:Pyrazoles; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D003692:Delayed-Action Preparations; D011720:Pyrazoles; D013449:Sulfonamides; C026784:acemetacin; D000068579:Celecoxib; D007213:Indomethacin